Proactive Investors - Run By Investors For Investors

ImmuPharma chairman more optimistic on results for its Lupuzor drug

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) tells Proactive that there is a strong indication that in certain populations of lupus patients, its Lupuzor drug works very effectively. 

McCarthy was talking after a deeper dive into the data generated by its phase III clinical trial of the company's flagship drug candidate.

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full IMM profile View Profile

ImmuPharma PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use